Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

30.86 +0.53 (+1.75%)
Streaming Delayed Price Updated: 12:53 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
3 Game-Changing Stocks to Buy in March ↗
Innovation is in these companies' DNA. 
Via The Motley Fool
News headline image
The Top 7 Growth Stocks in Biotech ↗
The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term. 
Via InvestorPlace
News headline image
Where Beam Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
News headline image
Analyst Ratings for Beam Therapeutics ↗
 
Via Benzinga
4 Analysts Have This to Say About Beam Therapeutics ↗
 
Via Benzinga
BMO Capital Upgrades Beam Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Better Buy: Beam Therapeutics or Intellia Therapeutics? ↗
The two clinical-stage gene-editing companies have good long-term prospects. 
Via The Motley Fool
News headline image
Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129% ↗
Cathie Wood is bullish about these stocks. And so are Wall Street analysts. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023 ↗
 
Via Benzinga
News headline image
7 CRISPR Stocks With the Best Long-Term Potential ↗
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
News headline image
5 Top Stocks for February ↗
These growth stocks have more room to run. 
Via The Motley Fool
News headline image
3 Great Growth Stocks Down 20% or More to Buy Now ↗
These beaten-down stocks could be poised for major rebounds. 
Via The Motley Fool
News headline image
A New Bull Market Is Coming: 3 Stocks That Could Skyrocket ↗
Aggressive investors should check out these stocks. 
Via The Motley Fool
News headline image
3 Stocks That Could Create Lasting Generational Wealth ↗
Making money that spans generations requires thinking big. 
Via The Motley Fool
News headline image
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
News headline image
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away' ↗
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams. 
Via Benzinga
News headline image
Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
3 Under-the-Radar Biotech Stocks to Buy in 2022 ↗
The attraction of all three biotech stocks is their potential. 
Via The Motley Fool
News headline image
Analyst Beefs Up Beam Therapeutics Price Target, Says 'Reward Is Now Skewed To Upside' ↗
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022 ↗
 
Via Benzinga
News headline image
Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday ↗
Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to close... 
Via Benzinga
News headline image
7 ‘Next Big Things’ for Investors to Buy for 2023 ↗
The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown. 
Via InvestorPlace
News headline image
Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant
Data from ESCAPE-1 and ESCAPE-2 Approaches to Be Presented During Poster Sessions at the 64th ASH Annual Meeting and Exposition 
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
Beam Ranked No. 4 in Large Companies Category, Marking Fourth Consecutive Year as Top Workplace in Massachusetts 
From Beam Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022 ↗
 
Via Benzinga
News headline image
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts ↗
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding... 
Via Benzinga
News headline image
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
From Beam Therapeutics
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.